Swiss pharmaceuticals giant Novartis has announced job cuts at its Horsham site in West Sussex. A company spokesman said Novartis planned to reduce the total workforce of 950 at the site by 550. The move comes as a further blow to the UK's pharmaceutical research and development (R&D) industry. In February, Pfizer said would close its research and development facility at Sandwich in Kent, which employs 2,400 people. Of the 950 employees on the Horsham campus approximately 330 are dedicated to respiratory research. "With significant changes in healthcare systems aimed to contain or cut cost, this critical assessment and the subsequent potential changes to the Novartis UK organisation are key to maintain significant investment in innovative drugs and our research efforts in the UK," said Sue Webb, general manager at Novartis, in a statement. The drugs industry in general is scaling back investment in R&D, despite the need to find new medicines as the patents on older drugs expire. The Novartis and Pfizer plans will be implemented over the next two years.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac... -
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma... -
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th... -
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after... -
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y... -
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ... -
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment